EyeCRO, MPI Research partner on large mammalian preclinical models

01-May-2017 - Last updated on 02-May-2017 at 15:50 GMT

EyeCRO's expanded lab in Ann Arbor, MI features 3,500 sq.ft. of wet-research laboratory space. (Image: EyeCRO)

EyeCRO and MPI Research are co-developing large mammalian preclinical models for ophthalmic diseases as clients look to perform pharmacology studies in larger species.

The ongoing partnership combines EyeCROs knowledge in developing and implementing research models, “while the team at MPI has skilled veterinary ophthalmologists and scientists who have substantial experience working with larger species,” Rafal Farjo, Ph.D., Chief Executive Officer, EyeCRO LLC, told Outsourcing-Pharma.com

“While our smaller models can recapitulate many of the disease pathologies, several clients have indicated a desire to perform pharmacology studies in larger species where they can also evaluate ocular tolerability and pharmacokinetics,” Farjo added.

The models will include those for age-related macular degeneration and diabetic retinopathy.

Working together, Farjo said the companies can “implement a synergistic approach to develop and commercialize new large animal models in an accelerated timeframe.”

EyeCRO and MPI are co-authoring a poster together at the 2017 annual meeting for the Association for Research in Vision and Ophthalmology which takes place May 7 to May 11 in Baltimore.

EyeCRO has also announced the official opening of a new research and development site laboratory in Ann Arbor, Michigan for which it will be seeking full AAALAC accreditation.